Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

182
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
182
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

310
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
310
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

371
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
371
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

480
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
480
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

158
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
158

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

Postmortem MRI reveals distinct structural features in sudden unexpected death in epilepsy.

Epilepsia open·2026
Same author

A consensus roadmap for post-traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials.

Epilepsia·2026
Same author

The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.

CNS drugs·2026
Same author

The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil.

CNS drugs·2026
Same author

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add-on trials in drug-resistant focal epilepsy.

Epilepsia·2026

相关实验视频

Updated: Jun 20, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

新的疗法正在开发中.

Pavel Klein1, Rafal M Kaminski2, Matthias Koepp3

  • 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. kleinp@epilepsydc.com.

Nature reviews. Drug discovery
|July 22, 2024
PubMed
概括

是一种常见的大脑疾病,缺乏预防性治疗和有效控制30%的患者. 最近的进展提供了超过200种针对特定机制和预防策略的新疗法.

更多相关视频

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

722

相关实验视频

Last Updated: Jun 20, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

722

科学领域:

  • 神经学 神经学
  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 是一种流行的神经系统疾病,其特点是经常出现发作,经常伴有认知和精神问题,并增加死亡率.
  • 目前的抗发作药物 (ASM) 在至少30%的患者中是无效的,并且没有可用的预防性干预措施.
  • 遗传学,疾病模型和药物查方面的重大进展刺激了新型治疗方法的发展.

研究的目的:

  • 审查抗发作药物 (ASM) 治疗的最新进展.
  • 概述旨在治疗和预防的新型治疗方法的未来方向.
  • 突出转向基于机制的治疗和疾病预防策略的转变.

主要方法:

  • 关于研究和治疗开发的最新科学文献的综述.
  • 对新型治疗方法的临床前和临床管道的分析.
  • 评估的诊断和预测生物标志物的进展.

主要成果:

  • 目前有200多种新的疗法正在开发中,针对不同的机制.
  • 新兴疗法包括治疗的预防和基于机制的干预措施.
  • 诊断和预测生物标志物正在促进个性化的治疗.

结论:

  • 治疗领域正在从症状管理向疾病修饰和预防过渡.
  • 创新的疗法和生物标志物正在为更有效和个性化的治疗铺平道路.
  • 未来的研究应该集中在针对特定综合征开发向治疗和预防策略上.